OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	189
Strategies for targeting RNA with small molecule drugs	144
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	110
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	88
The root cause: why do so many drugs fail to translate from bench to bedside?	66
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	58
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	55
Advances in ion channel high throughput screening: where are we in 2023?	54
Advances in the discovery of drugs that treat pulmonary arterial hypertension	46
What is the plausibility that all drugs will be designed by computers by the end of the decade?	46
γ-Secretase: once and future drug target for Alzheimer’s disease	45
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	44
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	38
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	38
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	37
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder	36
Tools and techniques for the discovery of therapeutic aptamers: recent advances	36
Methods in marine natural product drug discovery: what’s new?	35
Phenotypic screening for new heart failure therapeutics: scalable animal modeling in zebrafish	35
The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery	34
A cautionary tale of paradox and false positives in cannabidiol research	33
The rules often neglected in current medicinal chemistry	33
Molecular hybridization: a powerful tool for multitarget drug discovery	32
The potential of microfluidic platforms for neuron differentiation and pain modeling in novel drug discovery	32
Water in drug design: pitfalls and good practices	32

C. elegans : a prominent platform for modeling and drug screening in neurological disorders	32
Virtual screening: hope, hype, and the fine line in between	32
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	31
Current challenges and future perspectives of drug discovery in China	30
An update on knowledge graphs and their current and potential applications in drug discovery	30
Novel insights into structure–activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration	30